RES also shows promise in overcoming drug resistance in SCLC by inhibiting the STAT3/VEGF pathway and P‐glycoprotein function, potentially resensitizing resistant cells to chemotherapy. This evidence concerns the gene STAT3 and small cell lung carcinoma.